Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

Hansen Dang, Yee Hui Yeo, Satoshi Yasuda, Chung‐Feng Huang, Etsuko Iio, Charles Landis, Dae Won Jun, Masaru Enomoto, Eiichi Ogawa, Pei‐Chien Tsai, An Le, Matthew Liu, Mayumi Maeda, Brian Nguyen, Nathan Ramrakhiani, Linda Henry, Ramsey Cheung, Akihiro Tamori, Takashi Kumada, Yasuhito Tanaka, Ming‐Lung Yu, Hidenori Toyoda, Mindie H. Nguyen – 14 October 2019

Changing Etiologies and Prognostic Factors in Pediatric Acute Liver Failure

Manuel Mendizabal, Marcelo Dip, Ezequiel Demirdjian, Leandro Lauferman, Susana Lopez, Julia Minetto, Alejandro Costaguta, Carolina Rumbo, Ivone Malla, María Camila Sanchez, Esteban Halac, Guillermo Cervio, Miriam Cuarterolo, Marcela Galoppo, Oscar Imventarza, Liliana Bisgniano, Daniel D’Agostino, Fernando Rubinstein – 13 October 2019 – After the implementation of universal hepatitis A virus vaccination in Argentina, the outcome of pediatric acute liver failure (PALF) remains unknown.

qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

Feng Liu, George Boon‐Bee Goh, Dina Tiniakos, Aileen Wee, Wei‐Qiang Leow, Jing‐Min Zhao, Hui‐Ying Rao, Xiao‐Xiao Wang, Qin Wang, Wei‐Keat Wan, Kiat‐Hon Lim, Manuel Romero‐Gomez, Salvatore Petta, Elisabetta Bugianesi, Chee‐Kiat Tan, Stephen A. Harrison, Quentin M. Anstee, Pik‐Eu Jason Chang, Lai Wei – 10 October 2019

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B

Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Henry L.Y. Chan, Maria Buti, Marc G. Ghany, Anuj Gaggar, Jenny C. Yang, George Wu, John F. Flaherty, G. Mani Subramanian, Stephen Locarnini, Patrick Marcellin – 10 October 2019 – In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown.

Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice

Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Sharon C. Cunningham, Alexandra Sharland, Ian E. Alexander, Peter W. Angus, Chandana B. Herath – 10 October 2019 – There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a disease that commonly results in liver failure. Angiotensin (Ang) II of the renin Ang system (RAS) is a potent profibrotic peptide, and Ang converting enzyme 2 (ACE2) of the alternate RAS breaks down Ang II to antifibrotic peptide Ang‐(1‐7).

Subscribe to